Education
About Us
Working with TipRanks
Follow Us
Envista Holdings (NVST)
NYSE:NVST
Top Page
Envista Holdings
(NYSE:NVST)
Select Model
Select Model
Rating:69Neutral
Price Target:
$24.00
▲(1.61% Upside)
Envista Holdings' overall stock score is driven primarily by strong earnings call results and positive technical indicators, indicating a favorable outlook. However, the high P/E ratio suggests overvaluation, and profitability challenges remain a concern. Continued focus on improving net margins and navigating external challenges will be crucial for future success.
Positive Factors
Revenue Growth
The company's consistent revenue growth indicates strong market demand and effective business strategies, contributing to long-term stability.
Operational Efficiency
Improved operational efficiency through cost reductions enhances profitability and allows for reinvestment in growth initiatives.
Market Share Gains
Increasing market share across key segments strengthens competitive positioning and supports sustained revenue growth.
Negative Factors
Profitability Challenges
Low net profit margins indicate ongoing profitability challenges, which could hinder long-term financial health and investment capacity.
Tariff Headwinds
Persistent tariff costs can erode margins, impacting profitability and potentially leading to higher prices or cost-cutting measures.
China Market Uncertainty
Uncertainty in the China market poses risks to revenue and growth, especially if VBP impacts materialize, affecting strategic planning.
Envista Holdings (NVST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.88B
Dividend YieldN/A
Average Volume (3M)2.00M
Price to Earnings (P/E)282.5
Beta (1Y)0.93
Revenue Growth4.73%
EPS GrowthN/A
CountryUS
Employees12,300
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)0.32
Shares Outstanding164,426,240
10 Day Avg. Volume1,527,299
30 Day Avg. Volume1,997,745
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.13
Price to Sales (P/S)1.32
P/FCF Ratio10.97
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit2.65
Enterprise Value/Ebitda11.26
Forecast
1Y Price Target
$22.38Price Target Upside-5.25% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Envista Holdings Business Overview & Revenue Model
Company DescriptionEnvista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
How the Company Makes MoneyEnvista generates revenue primarily through the sale of dental products and equipment across various segments. Its key revenue streams include orthodontic devices, restorative materials, and digital imaging products. The company benefits from a strong distribution network and strategic partnerships with dental professionals and institutions, enabling it to reach a wide customer base. Additionally, Envista invests in research and development to introduce new technologies and improve existing products, which contributes to its competitive advantage and revenue growth.
Envista Holdings Earnings Call Summary
Earnings Call Date:Oct 29, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 05, 2026
Earnings Call Sentiment Positive
The earnings call for Envista Holdings highlighted strong financial performance and growth across several business segments. The company achieved significant milestones in its Spark aligner business and raised its full-year guidance. However, challenges like tariff costs and uncertainties in the China market due to potential VBP impacts were noted. Overall, the positives in revenue growth, market share gains, and operational efficiency improvements outweigh the negatives.Q3-2025 Updates
Positive Updates
Strong Revenue and Earnings Growth
Envista Holdings reported Q3 core growth of 9%, supported by a Spark deferral benefit. Excluding this, core growth was around 5%. Adjusted EBITDA margin increased by more than 500 basis points from Q3 '24 to 14.5%. Adjusted EPS more than doubled to $0.32.
Full-Year Guidance Raised
Envista increased its full-year 2025 guidance for core revenue growth to approximately 4% and adjusted EPS to $1.10 to $1.15. This reflects the company's strong year-to-date performance and momentum.
Spark Aligner Milestone
Envista shipped its 1 millionth Spark aligner case and achieved positive operating profit for Spark in Q3. The Spark business is nearing $300 million in revenue since launching in 2019.
Positive Market Share Gains
Envista gained market share in all major businesses except implants, where it held its share. The company achieved double-digit growth in consumables and had positive growth in diagnostics for a second consecutive quarter.
Operational Efficiency Improvements
Envista reduced G&A expenses by more than 12% year-to-date while maintaining high customer service levels. The company also made significant R&D investments.
Negative Updates
Tariff Headwinds
Increased tariff costs compressed margins by about 140 basis points in Q3. Envista expects around $10 million in tariffs per quarter moving forward.
China Market Uncertainty
Ongoing uncertainty due to potential Volume-Based Procurement (VBP) impacts, especially for orthodontics and future implants. The timing and specifics of these impacts remain unclear.
Mixed Performance in Orthodontics
Brackets & Wires were flat year-on-year due to VBP preparations in China and prior Q2 buy-ahead impacts.
Company Guidance
During the Envista Holdings Corporation's Q3 2025 earnings call, the company reported strong financial performance with a core growth of 9%, which included a Spark deferral benefit, and an adjusted EBITDA margin of 14.5%, up by over 500 basis points from the previous year. The adjusted EPS was $0.32, a significant increase from the previous year's $0.12. Year-to-date, Envista achieved core growth of approximately 3% and an adjusted EBITDA margin of around 13%, with an adjusted EPS of $0.82, marking a 67% increase from the prior year. The company has raised its full-year guidance, now anticipating core revenue growth of approximately 4% and adjusted EPS between $1.10 and $1.15, while maintaining the EBITDA margin guidance at 14%. In Q3, Envista's Specialty Products and Technology segment grew by 13% year-over-year, with core sales up 10.6%. Meanwhile, the Equipment and Consumables segment saw a core sales increase of 7.3%. The company also generated $68 million in free cash flow during the quarter.Envista Holdings Financial Statement Overview
Summary
Envista Holdings demonstrates a stable financial position with moderate growth and profitability. Revenue and operational efficiency are improving, but profitability remains a concern with low net margins. The balance sheet is strong with manageable leverage, and cash flow metrics indicate effective cash management.Income Statement
Envista Holdings shows a modest revenue growth rate of 2.7% in the TTM period, indicating a positive trajectory. The gross profit margin remains strong at 55.4%, but the net profit margin is quite low at 0.58%, suggesting profitability challenges. The EBIT and EBITDA margins have improved compared to previous periods, reflecting better operational efficiency.Balance Sheet
The company's debt-to-equity ratio is moderate at 0.52, indicating a balanced approach to leverage. The return on equity is low at 0.50%, pointing to limited profitability from equity. However, the equity ratio is healthy, suggesting a strong asset base relative to liabilities.Cash Flow
Free cash flow growth is positive at 1.78%, and the free cash flow to net income ratio is robust at 0.87, indicating efficient cash generation relative to earnings. The operating cash flow to net income ratio is moderate, reflecting stable cash flow management.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.62B | 2.51B | 2.57B | 2.57B | 2.51B | 1.93B |
| Gross Profit | 1.45B | 1.39B | 1.45B | 1.49B | 1.46B | 1.07B |
| EBITDA | 341.90M | 279.50M | 463.00M | 497.70M | 496.00M | 260.20M |
| Net Income | 15.30M | -1.12B | -100.20M | 243.10M | 340.50M | 33.30M |
Balance Sheet | ||||||
| Total Assets | 5.64B | 5.35B | 6.61B | 6.59B | 6.57B | 6.88B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.07B | 940.00M | 606.90M | 1.07B | 888.90M |
| Total Debt | 1.60B | 1.55B | 1.65B | 1.53B | 1.48B | 1.98B |
| Total Liabilities | 2.55B | 2.42B | 2.43B | 2.38B | 2.52B | 3.15B |
| Stockholders Equity | 3.09B | 2.93B | 4.17B | 4.21B | 4.06B | 3.72B |
Cash Flow | ||||||
| Free Cash Flow | 262.50M | 302.70M | 217.50M | 107.00M | 306.90M | 236.20M |
| Operating Cash Flow | 300.10M | 336.50M | 275.70M | 182.70M | 361.60M | 283.90M |
| Investing Cash Flow | -43.00M | -54.60M | -62.40M | -657.30M | 262.70M | -69.10M |
| Financing Cash Flow | -146.60M | -103.70M | 118.90M | 12.50M | -465.60M | 492.50M |
Envista Holdings Technical Analysis
Positive
23.62
Price Trends
20.91
Positive
20.74
Positive
19.54
Positive
Market Momentum
0.57
Negative
70.88
Negative
86.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVST, the sentiment is Positive. The current price of 23.62 is above the 20-day moving average (MA) of 22.21, above the 50-day MA of 20.91, and above the 200-day MA of 19.54, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 70.88 is Negative, neither overbought nor oversold. The STOCH value of 86.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVST.
Envista Holdings Risk Analysis
Envista Holdings disclosed 49 risk factors in its most recent earnings report. Envista Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Envista Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $3.88B | 282.54 | 0.50% | ― | 4.73% | ― | |
55 Neutral | $6.13B | -20.03 | -4.69% | ― | 6.23% | 17.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.99B | -14.80 | -34.78% | ― | ― | -34.96% | |
49 Neutral | $1.23B | -7.13 | -16.81% | ― | 7.16% | 3.95% | |
46 Neutral | $2.49B | -2.82 | -44.44% | 5.61% | -7.08% | -113.81% | |
46 Neutral | $1.31B | -21.85 | -16.90% | ― | 15.23% | 38.79% |
* Healthcare Sector Average
NVST
Envista Holdings
23.62
4.63
24.38%
XRAY
DENTSPLY SIRONA
12.48
-5.31
-29.85%
IRON
Disc Medicine
79.29
20.55
34.98%
CLOV
Clover Health Investments
2.53
-1.19
-31.99%
ABCL
AbCellera Biologics
4.11
1.11
37.00%
BLCO
Bausch + Lomb Corporation
17.30
-0.07
-0.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.